Answers are grounded in this paper and cite their sources.
Introduction: Severe thrombocytopenia (< 50×109/L) occurs in 20–35% of septic ICU patients and carries 40–50% 28-day mortality if persisting >7 days. Recombinant human thrombopoietin (rhTPO) may restore platelet counts and improve outcomes, but its efficacy and safety remain unproven. Methods: Multicenter, open-label RCT (Apr 2019–Dec 2024) in 8 Chinese ICUs randomized 204 septic patients with severe thrombocytopenia (< 50×109/L) to rhTPO 15,000 U/day for 7 days (n=101) or placebo (n=103). The primary endpoint was 28-day all-cause mortality, and secondary endpoints included platelet count changes, clinical platelet recovery time, blood product transfusion volume, infection biomarkers, and organ function indicators. Results: A total of 188 patients (98 in the rhTPO group and 90 in the placebo group) were included in the modified intention-to-treat analysis, with balanced baseline characteristics between groups. For the primary endpoint, the 28-day mortality was 17.3% (17/98) in the rhTPO group and 24.4% (22/90) in the placebo group, with a hazard ratio (HR) of 0.82 (95% confidence interval [CI]: 0.53-1.27, P=0.308), without statistical significance. Subgroup analysis showed that rhTPO significantly reduced 28-day mortality in patients < 65 years old, with systolic blood pressure ≥118 mmHg, and total bilirubin < 28 μmol/L (P< 0.05). In terms of platelet dynamics, the rhTPO group showed an upward trend in platelet counts on days 10 and 14 (P=0.069 and P=0.09), and platelet recovery was faster in patients < 65 years old (P< 0.05). In terms of safety, the incidence of adverse events was similar between the two groups, and rhTPO did not increase the risk of bleeding or thromboembolism. Conclusions: rhTPO did not show overall survival benefit in unselected septic patients with severe thrombocytopenia, but it may accelerate platelet recovery and reduce mortality in specific subgroups (aged < 65 years, stable systolic blood pressure, and low total bilirubin) with good safety. Future biomarker-stratified trials are needed to further validate and optimize the precision application of rhTPO in septic patients.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: